医学
舒尼替尼
肾细胞癌
耐受性
内科学
置信区间
相对风险
荟萃分析
免疫系统
肿瘤科
胃肠病学
不利影响
免疫学
作者
Alessandro Rizzo,Giacomo Nuvola,Gennaro Palmiotti,Selma Ahcene-Djaballah,Veronica Mollica,Matteo Rosellini,Andrea Marchetti,Maria Arcangela Nigro,Elisa Tassinari,Serena Macrini,Francesco Massari
出处
期刊:Immunotherapy
[Future Medicine]
日期:2023-02-01
卷期号:15 (2): 117-126
被引量:1
标识
DOI:10.2217/imt-2022-0023
摘要
Aims: We performed a meta-analysis to assess the relative risk (RR) of all-grade and grade 3–4 hypertransaminasemia in studies comparing immune-based combinations with sunitinib in treatment-naive patients with advanced renal cell carcinoma. Materials & methods: Outcomes of interest included all-grade and grade 3–4 hypertransaminasemia measured as RRs and 95% confidence intervals (CIs). Results: RRs for all-grade hypertransaminasemia were 1.73 (95% CI: 1.25–2.4) and 1.63 (95% CI: 1.25–2.12) in patients receiving immunocombinations and sunitinib, respectively. The pooled RRs for grade 3–4 hypertransaminasemia were 3.24 and 3.04 in patients treated with immunocombinations or sunitinib. Conclusion: Immune-based combinations were associated with higher hypertransaminasemia risk. Physicians should pay attention to these common but overlooked events. Careful monitoring of tolerability remains a crucial need.
科研通智能强力驱动
Strongly Powered by AbleSci AI